Clinical Trial Update: DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating DTPA chelation for symptoms in gadolinium deposition disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gadolinium Deposition Disease

Drugs mentioned

• DTPA chelation (Diethylenetriaminepenta-acetic acid (DTPA))

Snippet

Sponsor: Stanford University | Conditions: Gadolinium Deposition Disease | EARLY_Phase 1 | Status: WITHDRAWN